PMID- 33236399
OWN - NLM
STAT- MEDLINE
DCOM- 20210802
LR  - 20210802
IS  - 1399-3062 (Electronic)
IS  - 1398-2273 (Linking)
VI  - 23
IP  - 2
DP  - 2021 Apr
TI  - Successful treatment of CMV, EBV, and adenovirus tissue infection following 
      HLA-mismatched allogeneic stem cell transplant using infusion of third-party T 
      cells from multiple donors in addition to antivirals, rituximab, and surgery.
PG  - e13528
LID - 10.1111/tid.13528 [doi]
AB  - Viral infections, principally cytomegalovirus, Epstein Barr virus (EBV) and 
      adenovirus, are a leading cause of morbidity and mortality after allogeneic stem 
      cell transplantation. The use of systemic antivirals is limited by limited 
      efficacy and organ toxicities. Inability to clear infection is exacerbated by 
      transplant-related immunosuppression and prophylaxis or treatment of acute graft 
      versus host disease. We report the first patient to clear three serious viral 
      infections after stem cell transplant using third-party donor partially human 
      leukocyte antigen (HLA) matched virus-specific cytotoxic T cells. The patient, a 
      53 year old female with transplanted for relapsed leukemia, with severe graft 
      versus host disease received five T cell infusions from three separate donors 
      that ultimately cleared serious systemic infections with cytomegalovirus and 
      adenovirus, and an EBV-driven lymphoma. Systemic antivirals had resulted in 
      failed clinical responses. Use of repeated infusions of partially HLA matched 
      virus-specific T cells from banks containing cryopreserved cells should be 
      strongly considered in transplant recipients with single or multiple refractory 
      viral infections.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Di Ciaccio, Pietro R
AU  - Di Ciaccio PR
AUID- ORCID: 0000-0002-9282-8619
AD  - Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.
FAU - Avdic, Selmir
AU  - Avdic S
AD  - Stem Cell Transplant and Cell Therapies Program, Westmead Hospital, Sydney, NSW, 
      Australia.
FAU - Sutrave, Gaurav
AU  - Sutrave G
AD  - Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.
AD  - Stem Cell Transplant and Cell Therapies Program, Westmead Hospital, Sydney, NSW, 
      Australia.
FAU - Clancy, Leighton
AU  - Clancy L
AD  - Stem Cell Transplant and Cell Therapies Program, Westmead Hospital, Sydney, NSW, 
      Australia.
FAU - Withers, Barbara
AU  - Withers B
AD  - Stem Cell Transplant and Cell Therapies Program, Westmead Hospital, Sydney, NSW, 
      Australia.
FAU - Blyth, Emily
AU  - Blyth E
AD  - Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.
AD  - Stem Cell Transplant and Cell Therapies Program, Westmead Hospital, Sydney, NSW, 
      Australia.
FAU - McLeod, Duncan
AU  - McLeod D
AD  - Department of Pathology, Westmead Hospital, Sydney, NSW, Australia.
FAU - Gottlieb, David J
AU  - Gottlieb DJ
AD  - Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.
AD  - Stem Cell Transplant and Cell Therapies Program, Westmead Hospital, Sydney, NSW, 
      Australia.
AD  - Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, 
      NSW, Australia.
LA  - eng
PT  - Case Reports
DEP - 20201206
PL  - Denmark
TA  - Transpl Infect Dis
JT  - Transplant infectious disease : an official journal of the Transplantation 
      Society
JID - 100883688
RN  - 0 (Antiviral Agents)
RN  - 0 (HLA Antigens)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Adenoviridae/immunology
MH  - Antiviral Agents/*therapeutic use
MH  - *Cytomegalovirus Infections
MH  - *Epstein-Barr Virus Infections
MH  - Female
MH  - HLA Antigens
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Herpesvirus 4, Human/immunology
MH  - Humans
MH  - Middle Aged
MH  - Rituximab/*therapeutic use
MH  - Stem Cell Transplantation
OTO - NOTNLM
OT  - allogeneic stem cell transplant
OT  - cellular therapy
OT  - virus-specific T cells
EDAT- 2020/11/26 06:00
MHDA- 2021/08/03 06:00
CRDT- 2020/11/25 05:51
PHST- 2020/10/18 00:00 [revised]
PHST- 2020/08/11 00:00 [received]
PHST- 2020/11/15 00:00 [accepted]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/08/03 06:00 [medline]
PHST- 2020/11/25 05:51 [entrez]
AID - 10.1111/tid.13528 [doi]
PST - ppublish
SO  - Transpl Infect Dis. 2021 Apr;23(2):e13528. doi: 10.1111/tid.13528. Epub 2020 Dec 
      6.